An Open Label, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics Following Oral Administration of [14C]AZD2066 to Healthy Male Subjects.

Trial Profile

An Open Label, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics Following Oral Administration of [14C]AZD2066 to Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs AZD 2066 (Primary)
  • Indications Gastro-oesophageal reflux; Neuropathic pain
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 Feb 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
    • 24 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Jan 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top